An Abbreviated History of Aldosterone Metabolism, Current and Future Challenges
Experimental and Clinical Endocrinology & Diabetes · 01.08.2023 · 131 (07/08) · 386-393
DOI: 10.1055/a-2054-1062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, erschienen am 01.08.2023. Verfasst von Celso E Gomez-Sanchez und 1 weiteren Autor:innen. Beteiligte Einrichtung: G.V. (Sonny) Montgomery VA Medical Center and Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS, Unite…. Hauptthemen laut MEDLINE: Hypertension, Hyperaldosteronism. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 100 Literaturangaben. Gefördert von: National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
The initial isolation of adrenal steroids from large quantities of animal adrenals resulted in an amorphous fraction resistant to crystallization and identification and had potent effects on electrolyte transport. Aldosterone was eventually isolated and identified in the fraction and was soon shown to cause hypertension when in excess. The autonomous and excessive production of aldosterone, primary aldosteronism, is the most common cause of secondary hypertension. Aldosterone is metabolized in the liver and kidney, and its metabolites are conjugated with glucuronic acid for excretion. The most common liver metabolite is 3α,5β-tetrahydroaldosterone-3-glucuronide, while that of the kidney is aldosterone-18-oxo-glucuronide. In terms of their value, especially the aldosterone-18-oxo-glucuronide, is commonly used for the diagnosis of primary aldosteronism because they provide an integrated value of the total daily production of aldosterone. Conversion of aldosterone to 18-oxo-glucuronide is impeded by drugs, like some common non-steroidal anti-inflammatory drugs that compete for UDP-glucuronosyltransferase-2B7, the most important glucuronosyltransferase for aldosterone metabolism. Tetrahydroaldosterone is the most abundant metabolite and the most reliable for the diagnosis of primary aldosteronism, but it is not commonly measured.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- G.V. (Sonny) Montgomery VA Medical Center and Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS, United States of America.
Förderung
- National Heart, Lung, and Blood Institute
Zitieren
APA
Gomez-Sanchez, C. E., & Gomez-Sanchez, E. P. (2023). An Abbreviated History of Aldosterone Metabolism, Current and Future Challenges. Experimental and Clinical Endocrinology & Diabetes, 131(07/08), 386-393. https://doi.org/10.1055/a-2054-1062
Vancouver
Gomez-Sanchez CE, Gomez-Sanchez EP. An Abbreviated History of Aldosterone Metabolism, Current and Future Challenges. Experimental and Clinical Endocrinology & Diabetes. 2023;131(07/08):386-393. doi:10.1055/a-2054-1062
BibTeX
@article{GomezSanchez2023,
author = {Gomez-Sanchez, Celso E and Gomez-Sanchez, Elise P},
title = {An Abbreviated History of Aldosterone Metabolism, Current and Future Challenges},
journal = {Experimental and Clinical Endocrinology & Diabetes},
year = {2023},
volume = {131},
number = {07/08},
pages = {386--393},
doi = {10.1055/a-2054-1062}
}
EUVIMED